MDGL Madrigal Pharmaceuticalsdata gap · 56% coveragelimited data
Health Care · Pharmaceutical Preparations · close $449.74 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Madrigal Pharmaceuticals (MDGL) has a ThetaGrade House Rating of 39/100 (grade D), ranking #86 of 150 in Health Care. Its strongest pillars are growth (66) and balance sheet (39); its weakest is profitability (14). Data gap: 6 factors without usable data, so 56% of the method weight is covered. TTM revenue growth is 149.0% and operating margin -25.1%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, EPS growth YoY (TTM), 4Q gross-margin change, Net debt / EBITDA, P/E (inverted). Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 56% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 66| Revenue growth YoY (TTM) (22.2%) | 149.0% | 97 |
| EPS growth YoY (TTM) (0.0%)data gap | — | — |
| Revenue acceleration (11.1%) | -55.7% | 3 |
Profitability
weight 18.5% (→20.0%) · 14| Operating margin (20.0%) | -25.1% | 14 |
| 4Q gross-margin change (0.0%)data gap | — | — |
Balance sheet
weight 18.5% (→20.0%) · 39| Net debt / EBITDA (0.0%)data gap | — | — |
| Current ratio (11.4%) | 3.20 | 62 |
| Interest coverage (8.6%) | -14.46× | 9 |
Cash flow
weight 12.33% (→13.3%) · 15| FCF margin (6.7%) | -19.8% | 13 |
| FCF yield (6.7%) | -1.8% | 18 |
Valuation
weight 12.33% (→13.3%) · 32| P/E (inverted) (0.0%)data gap | — | — |
| EV/Sales (inverted) (13.3%) | 8.13× | 32 |
Technicals (EOD)
| RSI(14) | 24.7 |
| EMA 9 / 21 | 467.99 / 487.10 |
| 200-day SMA | 505.11 |
| Volume vs 20d avg | 1.28× |
| 20-day return | -15.8% |
Exit-rule monitor
- EXITRating break: House Rating below 60
- EXITBalance-sheet stress: negative free cash flow (latest FY)
- WATCHTrend: close below 200-day average
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Operating income: OperatingIncomeLoss · Interest expense: InterestExpenseNonoperating · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close.
Get rating changes like MDGL's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is MDGL's House Rating?
- MDGL scores 39 out of 100 (grade D) as of 2026-10-16, ranking #86 of 150 Health Care stocks we cover.
- What do analysts say about MDGL?
- We do not have enough analyst-sentiment data to score this stock.
- When does MDGL report earnings next?
- MDGL's next earnings report is estimated for about 2026-11-03 (window 2026-10-28 to 2026-11-09), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is MDGL a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology